Syntis Bio
Boston
About Syntis Bio
Syntis Bio operates as a late-stage preclinical company that develops oral therapies for obesity, diabetes, and rare diseases. The company's drug uses novel formulations for oral therapies that target specific tissues, enabling users to increase bioavailability. Its oral therapies harness the small intestine’s biology to provide more accessible, effective, and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. It is rapidly advancing a pipeline of oral therapies engineered for targeted activity in the small intestine, the body’s nexus for metabolic control, digestion, and drug absorption.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $53.4M
- Funding stage: Early Stage Venture
- Last round: Grant (Jul 2025)
- Website: syntis.bio
- Phone: [email protected]
Industries & Categories
Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/syntis-bio-113615 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.